BPDCN – Expert Insight Into a Rare Blood Cancer

Naveen Pemmaraju, MD, MD Anderson Cancer Center, Houston, TX Recorded on December 11, 2018 Join Drs. Naveen Pemmaraju and Ken Miller as they discuss the diagnosis, treatment, and management of blastic plasmacytoid dendritic cell neoplasm (BPDCN), an often misdiagnosed and highly aggressive hematologic malignancy. Dr. Pemmaraju is a hematologist/oncologist at MD Anderson Cancer Center in Houston, TX. On this episode, Dr. Pemmaraju discusses the origin of BPDCN, methods of diagnosing and treating this rare disease, and the progress being made in the field. BPDCN Drug Updates: On December 21, 2018, the U.S. Food and Drug Administration (FDA) approved ELZONRIS (tagraxofusp) — the first treatment for blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adult and pediatric patients two years and older. For additional drug information, please visit: www.LLS.org/Drugs. Naveen Pemmaraju, MD Associate Professor Department of Leukemia MD Anderson Cancer Center Houston, TX